Journal of Vaccine Research 2024, Vol.14, No.6, 307-315 http://medscipublisher.com/index.php/jvr 314 Gilca V., Sauvageau C., Panicker G., De Serres G., Ouakki M., and Unger E., 2018, Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - a randomized clinical trial, Vaccine, 36(46): 7017-7024. https://doi.org/10.1016/j.vaccine.2018.09.057 Godi A., Panwar K., Haque M., Cocuzza C., Andrews N., Southern J., Turner P., Miller E., and Beddows S., 2019, Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine, Vaccine, 37(18): 2455-2462. https://doi.org/10.1016/j.vaccine.2019.03.052 Guo S., Gu D.N., and Chen X., 2024, Development and influencing factors of female cancers, Cancer Genetics and Epigenetics, 12(1): 27-36. https://doi.org/10.5376/cge.2024.12.0004 Kamolratanakul S., and Pitisuttithum P., 2021, Human papillomavirus vaccine efficacy and effectiveness against cancer, Vaccines, 9(12): 1413. https://doi.org/10.3390/vaccines9121413 Jit M., Brisson M., Laprise J., and Choi Y., 2015, Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model, The BMJ, 350: 7584. https://doi.org/10.1136/bmj.g7584 Kim J., Choe Y., Park J., Cho J., Cheong C., Oh J., Park M., Shim E., and Yu S., 2023, Comparative effects of bivalent, quadrivalent, and nonavalent human papillomavirus vaccines in the prevention of genotype-specific infection: a systematic review and network meta-analysis, Infection and Chemotherapy, Online ahead of print. https://doi.org/10.3947/ic.2023.0064 Lin R., Jin H., and Fu X., 2023, Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis, Expert Review of Vaccines, 22: 1168-1178. https://doi.org/10.1080/14760584.2023.2287135 Mariz F., Bender N., Anantharaman D., Basu P., Bhatla N., Pillai M., Prabhu P., Sankaranarayanan R., Eriksson T., Pawlita M., Prager K., Sehr P., Waterboer T., Müller M., and Lehtinen M., 2020, Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines, NPJ Vaccines, 5: 1-10. https://doi.org/10.1038/s41541-020-0165-x Mariz F., Gray P., Bender N., Eriksson T., Kann H., Apter D., Paavonen J., Pajunen E., Prager K., Sehr P., Surcel H., Waterboer T., Müller M., Pawlita M., and Lehtinen M., 2021, Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials, The Lancet Infectious Diseases, 21(10): 1458-1468. https://doi.org/10.1016/S1473-3099(20)30873-2 Markowitz L., Drolet M., Pérez N., Jit M., and Brisson M., 2018, Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs, Vaccine, 36(32 Pt A): 4806-4815. https://doi.org/10.1016/j.vaccine.2018.01.057 Mason J., 2024, Multiplex immunofluorescence in colorectal cancer: a retrospective analysis from SCOT and QUASAR 2 Trials, Cancer Genetics and Epigenetics, 12(1): 66-69. https://doi.org/10.5376/cge.2024.12.0008 Mühr L., Eklund C., Lagheden C., Eriksson T., Pimenoff V., Gray P., Lehtinen M., and Dillner J., 2022, Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses, The Journal of Infectious Diseases, 226: 1195-1199. https://doi.org/10.1093/infdis/jiac190 Ng S., Hutubessy R., and Chaiyakunapruk N., 2018, Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine, gender-neutral and multiple age cohort vaccination, Vaccine, 36(19): 2529-2544. https://doi.org/10.1016/j.vaccine.2018.03.024 Oketch S., Ochomo E., Orwa J., Mayieka L., and Abdullahi L., 2023, Communication strategies to improve human papillomavirus (HPV) immunisation uptake among adolescents in sub-Saharan Africa: a systematic review and meta-analysis, BMJ Open, 13: e067164. https://doi.org/10.1136/bmjopen-2022-067164 Phillips A., Patel C., Pillsbury A., Brotherton J., and Macartney K., 2018, Safety of human papillomavirus vaccines: an updated review, Drug Safety, 41: 329-346. https://doi.org/10.1007/s40264-017-0625-z Phua L., Choi H., Wu J., Jit M., Low J., Ng K., Pearce F., Hall C., and Aziz M., 2021, Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore, Vaccine, 39(22): 3013-3020. https://doi.org/10.1016/j.vaccine.2021.03.040 Portnoy A., Pedersen K., Trogstad L., Hansen B., Feiring B., Laake I., Smith M., Sy S., Nygård M., Kim J., and Burger E., 2021, Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: a model-based analysis, Preventive Medicine, 144: 106276. https://doi.org/10.1016/j.ypmed.2020.106276 Stanley M., Joura E., Yen G., Kothari S., Luxembourg A., Saah A., Walia A., Pérez G., Khoury H., Badgley D., and Brown D., 2021, Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines, Vaccine, 39(13): 1839-1853. https://doi.org/10.1016/j.vaccine.2021.01.060 Tang J., Li M., Zhao C., Shen D., Liu L., Zhang X., and Wei L., 2022, Therapeutic DNA vaccines against HPV-related malignancies: promising leads from clinical trials, Viruses, 14(2): 239.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==